Latest developments for uro-oncologist in the management of castration resistant prostate cancer
Welcome to the European Urology Advanced Prostate Cancer Resource Centre! The resource centre is freely accessible and it is our goal to inform you with the latest developments in the management of castration resistant prostate cancer.
To stay informed of new research and guidelines on this Resource Centre you can register for our email-alert.
You can visit the resource centre now, or see the latest published research below.
Video Interviews from EMUC 2014
 |
- Surgical techniques and imaging techniques should be tested the same as drugs
- The issues with techniques:
- Availability
- Reproducibility
- Cost
- Final remarks and take home message
|
|
 |
- CHAARTED Study results and its implications for the future
- Criteria of the CHAARTED Study
- The issues concerning cost and toxicity of chemotherapy
- Thanks to the results of the CHAARTED Study we now have an opportunity to rething how to treat metastatic disease
- Closing remarks and take home message
|
|
 |
Prostate cancer:
- An Avatar of the human disease
- How can the creation of an Avatar help research?
- Which steps will be taken next?
- What is needed to help research further?
- Closing remarks and take home message
|
|
Full Text Articles
PSA Flare With Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer
Salvatore L. Burgio, Vincenza Conteduca, Britt Rudnas, Francesco Carrozza, Enrico Campadelli, Emanuela Bianchi, Paolo Fabbri, Marco Montanari, Elisa Carretta, Cecilia Menna, Ugo De Giorgi
Clinical Genitourinary Cancer
Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer
Raya Leibowitz-Amit, Arnoud J. Templeton, Shabbir M. Alibhai, Jennifer J. Knox, Srikala S. Sridhar, Ian F. Tannock, Anthony M. Joshua
Journal of Geriatric Oncology, 1, 6, pages 23 - 28
Key publications:
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer
Prof Charles J Ryan, MD, Prof Matthew R Smith, MD, Prof Karim Fizazi, MD, et al.
The Lancet Oncology, Volume 16, No. 2, p152-160, February 2015
Oral ethinylestradiol in castration-resistant prostate cancer: a 10-year experience
Sciarra A, Gentile V, Cattarino S, Gentilucci A, Alfarone A, D'Eramo G, Salciccia S.
International Journal of Urology, 2015 Jan 22 : 98-103. Epub 2014 Sep 3.
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study
Michael T. Schweizer, Emmanuel S. Antonarakis, Hao Wang, A. Seun Ajiboye, Avery Spitz, Haiyi Cao, Jun Luo, Michael C. Haffner, Srinivasan Yegnasubramanian, Michael A. Carducci, Mario A. Eisenberger, John T. Isaacs and Samuel R. Denmeade
Science Translational Medicine 7 January 2015: Vol. 7, Issue 269
CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel
Wissing MD, Coenen JL, van den Berg P, Westgeest HM, van den Eertwegh AJ, van Oort IM, Bos MM, Bergman AM, Hamberg P, Ten Tije AJ, Los M, Lolkema MP, de Wit R, Gelderblom H
International Journal of Urology, 2015 Mar 15 ;136(6):E760-72.
|